| SARS-CoV-2 RBD-tetanus toxoid conjugate vaccine induces a strong neutralizing immunity in preclinical studies Y Valdes-Balbin, D Santana-Mederos, L Quintero, S Fernández, ... ACS Chemical Biology 16 (7), 1223-1233, 2021 | 88 | 2021 |
| Adjuvants are key factors for the development of future vaccines: lessons from the Finlay adjuvant platform O Pérez, B Romeu, O Cabrera, E González, A Batista-Duharte, A Labrada, ... Frontiers in immunology 4, 407, 2013 | 80 | 2013 |
| Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials M Eugenia-Toledo-Romaní, L Verdecia-Sánchez, M Rodríguez-González, ... Vaccine 40 (31), 4220-4230, 2022 | 50* | 2022 |
| A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial A Chang-Monteagudo, R Ochoa-Azze, Y Climent-Ruiz, ... The Lancet Regional Health–Americas 4, 2021 | 43 | 2021 |
| Biocompatible single-chain polymer nanoparticles loaded with an antigen mimetic as potential anticancer vaccine R Gracia, M Marradi, G Salerno, R Pérez-Nicado, A Pérez-San Vicente, ... ACS Macro Letters 7 (2), 196-200, 2018 | 39 | 2018 |
| Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein … R Puga-Gómez, Y Ricardo-Delgado, C Rojas-Iriarte, ... International Journal of Infectious Diseases 126, 164-173, 2023 | 24 | 2023 |
| A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity S Pérez-Rodríguez, M de la Caridad Rodríguez-González, R Ochoa-Azze, ... Vaccine 40 (13), 2068-2075, 2022 | 23 | 2022 |
| A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles D Santana-Mederos, R Perez-Nicado, Y Climent, L Rodriguez, ... RSC chemical biology 3 (2), 242-249, 2022 | 20 | 2022 |
| Expanding the scope of Ugi multicomponent bioconjugation to produce pneumococcal multivalent glycoconjugates as vaccine candidates AR Humpierre, A Zanuy, M Saenz, R Garrido, AV Vasco, R Pérez-Nicado, ... Bioconjugate Chemistry 31 (9), 2231-2240, 2020 | 19 | 2020 |
| A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A … A Chang-Monteagudo, R Ochoa-Azze, Y Climent-Ruiz, ... medRxiv, 2021.02. 22.21252091, 2021 | 16 | 2021 |
| Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses B Romeu, M Lastre, L Reyes, E González, Y Borrero, D Lescaille, R Pérez, ... Vaccine 32 (51), 6971-6978, 2014 | 10 | 2014 |
| Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children R Puga-Gómez, Y Ricardo-Delgado, C Rojas-Iriarte, ... medRxiv, 2022.03. 03.22271313, 2022 | 7 | 2022 |
| Dot Blot para determinar la identidad antigénica en vacunas conjugadas contra Streptococcus pneumoniae serotipo 19F O Cabrera-Blanco, M Pisonero-Triana, M Rodríguez-Bejerano, ... VacciMonitor 26 (1), 1-7, 2017 | 3 | 2017 |
| Diseño, desarrollo y evaluación preclínica de SOBERANA® 02: una vacuna cubana contra COVID-19 Y Valdés Balbín, D Santana Mederos, LM Quintero Moreno, ... Anales de la Academia de Ciencias de Cuba 13 (1), 2023 | 2 | 2023 |
| SOBERANA® Plus: refuerzo seguro y eficaz de la inmunidad natural pre-existente contra SARS-CoV-2 V Verez Bencomo, R Ochoa Azze, D García Rivera, Y Climent Ruiz, ... Anales de la Academia de Ciencias de Cuba 13 (1), 2023 | 2 | 2023 |
| Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children R Pérez-Nicado, C Massa, LM Rodríguez-Noda, A Müller, R Puga-Gómez, ... Vaccines 11 (11), 1636, 2023 | 1 | 2023 |
| Compositions of sars-cov-2 vaccines based on the receptor binding domain, expressed as a dimer, and the outer membrane vesicle of meningococcal group b bacteria YV Balbín, VGV Bencomo, DG Rivera, YC Ruiz, SF Castillo, LMR Noda, ... US Patent App. 18/021,731, 2023 | | 2023 |
| Estandarización de un ELISA para la cuantificación de anticuerpos IgG humanos contra células enteras de Bordetella pertussis D Martínez-Bedoya, R Pérez-Nicado, S Fernández-González, ... Vaccimonitor 32, 2023 | | 2023 |
| The Lancet Regional Health-Americas A Chang-Monteagudo, R Ochoa-Azze, Y Climent-Ruiz, ... | | 2021 |
